Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

PHASE3CompletedINTERVENTIONAL
Enrollment

514

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Parkinson's Disease
Interventions
DRUG

Rotigotine

2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks

DRUG

Rotigotine

4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks

OTHER

Placebo

Placebo transdermal patch applied daily

DRUG

Rotigotine

6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks

DRUG

Rotigotine

8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks

Trial Locations (77)

Unknown

Birmingham

Tuscaloosa

Gilbert

Peoria

Phoenix

Scottsdale

Little Rock

Fountain Valley

Fresno

Irvine

La Jolla

Loma Linda

Oxnard

Aurora

New Haven

Boca Raton

Bradenton

Jacksonville

Miami

Naples

Ocala

Ormond Beach

Pompano Beach

St. Petersburg

Sunrise

Atlanta

Decatur

Macon

Suwanee

Chicago

Anderson

Des Moines

Kansas City

Louisville

Southfield

Golden Valley

St Louis

Missoula

Omaha

Las Vegas

Commack

New York

Rochester

Raleigh

Salisbury

Columbus

Toledo

Greensburg

Souderton

Upland

Memphis

Lubbock

San Antonio

Midvale

South Ogden

Alexandria

Richmond

Roanoke

Virginia Beach

Kirkland

Spokane

Milwaukee

Santiago

Hyderbad

Bangalore

Mangalore

Mysore

Calicut

Thiruvananthapuram

Indore

Mumbai

Pune

Chennai

Aguascalientes

Monterrey

San Isidro

Santiago de Surco

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY